Loading
A phase 2/3 trial of irinotecan (and liposomal irinotecan), fluorouracil (5-FU), leucovorin (folinic acid), bevacizumab (glioblastoma use) and other drugs in colorectal cancer, run by Hebei Medical University Fourth Hospital, not yet recruiting.
A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer is a phase 2/3, randomised interventional study registered as NCT07585279 by Hebei Medical University Fourth Hospital, with a registry enrolment figure of 408 participants, started 2026-05-20 and due to reach its primary completion in 2031-02-28. Interventions recorded: Liposomal irinotecan + 5-FU/LV + bevacizumab + Enlonstobart; Irinotecan liposome + 5-FU/LV + Bevacizumab; Irinotecan + 5-FU/LV + Bevacizumab. Conditions listed: Metastatic Colorectal Cancer (CRC); Liposomal Irinotecan; Second-Line. Primary outcome: ORR. Colorectal eligibility wording from the registry: "Histologically or cytologically confirmed metastatic colon or rectal adenocarcinoma;". Sites: China. No results are recorded here; the registry entry is the source.
Shares Irinotecan (and liposomal irinotecan), Bevacizumab (glioblastoma use), Leucovorin (folinic acid), Fluorouracil (5-FU) and the tag colorectal-deep-dive.
Shares Irinotecan (and liposomal irinotecan), Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), Leucovorin (folinic acid) and the tag colorectal-deep-dive.
Shares Irinotecan (and liposomal irinotecan), Bevacizumab (glioblastoma use), Leucovorin (folinic acid), Fluorouracil (5-FU) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Leucovorin (folinic acid), Fluorouracil (5-FU), Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Leucovorin (folinic acid), Fluorouracil (5-FU), Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), Fluorouracil (5-FU), Topoisomerase-I inhibitors (and ADC payloads) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), Leucovorin (folinic acid), Topoisomerase-I inhibitors (and ADC payloads) and the tag colorectal-deep-dive.
Shares Irinotecan (and liposomal irinotecan), Bevacizumab (glioblastoma use), Topoisomerase-I inhibitors (and ADC payloads), Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.